Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2021.



Net sales for Q4 2021 rose 2% (+4% CER) to $582 million from Q4 2020, well

Premier Inc. to Participate in 2022 SVB Leerink Global Healthcare Conference on February 16, 2022
Premier Inc. to Participate in 2022 SVB Leerink Global Healthcare Conference on February 16, 2022


Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in a virtual fireside chat

Premier Inc. Receives 2022 Best in KLAS Award for Value-Based Care Consulting
Premier Inc. Receives 2022 Best in KLAS Award for Value-Based Care Consulting


Premier Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been awarded the 2022 Best in KLAS designation for Value-Based Care Consulting. The award was announced in

Chemed To Report Fourth-Quarter 2021 Earnings February 24, Related Conference Call To Be Held On February 25
Chemed To Report Fourth-Quarter 2021 Earnings February 24, Related Conference Call To Be Held On February 25


Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2021, on Thursday, February 24, 2022, following the close of trading

QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has gained additional momentum with the approval of the fourth

QIAGENs neue Generation des QuantiFERON-TB-Tests erhält Zulassung in China und erneute WHO-Empfehlung
QIAGENs neue Generation des QuantiFERON-TB-Tests erhält Zulassung in China und erneute WHO-Empfehlung


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass seine Tuberkulose (TB)-Testlösung QuantiFERON weiter an Dynamik gewonnen hat, nachdem die vierte Generation des

DGAP-Adhoc: Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets
DGAP-Adhoc: Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets
DGAP-Adhoc: Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets
DGAP-Adhoc: Evotec SE: Bayer stellt den klinischen Entwicklungskandidaten Eliapixant (BAY1817080) ein; Evotec erhält Rechte für alle P2X3-Assets zurück
DGAP-Adhoc: Evotec SE: Bayer stellt den klinischen Entwicklungskandidaten Eliapixant (BAY1817080) ein; Evotec erhält Rechte für alle P2X3-Assets zurück
DGAP-Adhoc: Evotec SE: Bayer stellt den klinischen Entwicklungskandidaten Eliapixant (BAY1817080) ein; Evotec erhält Rechte für alle P2X3-Assets zurück
Xencor to Present at Upcoming Investor Conferences
Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

AMN Healthcare Named as One of America’s Most Responsible Companies for 2022
AMN Healthcare Named as One of America’s Most Responsible Companies for 2022


For the third year in a row, AMN Healthcare (NYSE: AMN) has been named one of the country’s most responsible companies by Newsweek and Statista Action for its commitment and action to promote

Vifor Pharma appoints two new members to the Executive Committee
Vifor Pharma appoints two new members to the Executive Committee


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Pharma Group today announced the appointment of acting Chief Financial Officer Alexandros Sigalas and Group General Counsel Dr

Premier, Inc. Reports Fiscal Year 2022 Second Quarter Results
Premier, Inc. Reports Fiscal Year 2022 Second Quarter Results


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2022 second quarter ended December 31, 2021.



"Our

AMN Healthcare Again Recognized for Workplace Equity and Social Justice by Two Major Corporate Equality Indexes
AMN Healthcare Again Recognized for Workplace Equity and Social Justice by Two Major Corporate Equality Indexes


AMN Healthcare’s commitment to diversity, equity, equality, and inclusion has again been recognized in the business world with the company’s listing in two top corporate indexes that measure

Human Rights Campaign und Bloomberg würdigen QIAGENs Engagement im Bereich LGBTQ+- und Geschlechtergleichstellung
Human Rights Campaign und Bloomberg würdigen QIAGENs Engagement im Bereich LGBTQ+- und Geschlechtergleichstellung


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass das Engagement des Unternehmens für mehr Vielfalt und Gleichstellung von Geschlechtern am Arbeitsplatz durch die

QIAGEN’s Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes
QIAGEN’s Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its commitment to workplace diversity and gender equality has been recognized by inclusion in the U.S. LGBTQ+ Corporate

Gerresheimer AG: The leading supplier of injection vials Gerresheimer expands production in Wertheim
Gerresheimer AG: The leading supplier of injection vials Gerresheimer expands production in Wertheim
Gerresheimer AG: The leading supplier of injection vials Gerresheimer expands production in Wertheim
Gerresheimer AG: Der führende Anbieter von Injektionsfläschchen Gerresheimer erweitert Produktion in Wertheim
Gerresheimer AG: Der führende Anbieter von Injektionsfläschchen Gerresheimer erweitert Produktion in Wertheim
Gerresheimer AG: Der führende Anbieter von Injektionsfläschchen Gerresheimer erweitert Produktion in Wertheim
Charles River Expands Strategic Partnership With SAMDI Tech
Charles River Expands Strategic Partnership With SAMDI Tech


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of their strategic partnership with Chicago, Illinois-based SAMDI Tech, Inc. Under the existing partnership

AMN Healthcare Commitment Supports Underserved Nurses and Nurse Wellness
AMN Healthcare Commitment Supports Underserved Nurses and Nurse Wellness


In line with its commitment to the health and wellbeing of nurses, and for advancing diversity, equality, equity, and inclusion in the nursing profession, AMN Healthcare is donating to support the

QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance
QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has completed a U.S. government contract to equip public health laboratories across the country with the QIAcuity digital

QIAGEN rüstet im Auftrag von US-Bundesbehörde lokale Gesundheitslabore mit digitalem PCR-System QIAcuity für die COVID-19 Überwachung aus
QIAGEN rüstet im Auftrag von US-Bundesbehörde lokale Gesundheitslabore mit digitalem PCR-System QIAcuity für die COVID-19 Überwachung aus


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, im Rahmen der Erfüllung eines mit der US-Regierung geschlossenen Vertrags das digitale PCR-System QIAcuity landesweit an

DGAP-News: Evotec geht iPSC-basierte Forschungspartnerschaft mit Boehringer Ingelheim im Bereich Augenheilkunde ein
DGAP-News: Evotec geht iPSC-basierte Forschungspartnerschaft mit Boehringer Ingelheim im Bereich Augenheilkunde ein
DGAP-News: Evotec geht iPSC-basierte Forschungspartnerschaft mit Boehringer Ingelheim im Bereich Augenheilkunde ein
DGAP-News: Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology
DGAP-News: Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology
DGAP-News: Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology
DGAP-News: MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
DGAP-News: MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
DGAP-News: MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
DGAP-News: Frauenanteil in Führungspositionen: MorphoSys Nummer 1 in Deutschland im European Women on Boards Gender Equality Index Report
DGAP-News: Frauenanteil in Führungspositionen: MorphoSys Nummer 1 in Deutschland im European Women on Boards Gender Equality Index Report
DGAP-News: Frauenanteil in Führungspositionen: MorphoSys Nummer 1 in Deutschland im European Women on Boards Gender Equality Index Report